Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 11, 2023
Reporting Period: Event-based report for December 11, 2023.
Business Overview: The Company is a Delaware corporation focused on developing radiation sensitizer candidates. Its lead candidate, Ropidoxuridine, is intended for use in combination with radiation therapy to treat glioblastoma, a deadly brain tumor.
Key Financial Metrics
This filing is a current report regarding a regulatory milestone and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event reported is the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Ropidoxuridine. This submission supports the next phase of development for the Company's lead radiation sensitizer candidate.
Guidance, Outlook, and Risks
Management Commentary: The Company announced the IND submission via a press release furnished as Exhibit 99.1. The filing notes that the press release information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Outlook: The submission marks a progression in the development of Ropidoxuridine for the treatment of glioblastoma.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the inherent uncertainties of drug development and regulatory approval processes associated with the IND submission.
Key Facts for Investor Verification
- Verify the status of the FDA review of the Investigational New Drug (IND) application for Ropidoxuridine.
- Review the full text of the press release (Exhibit 99.1) for specific details on the next phase of development.
- Confirm the Company's cash runway and funding status, as this filing does not provide updated financial data.
- Monitor for future filings regarding the outcome of the FDA review or the initiation of clinical trials.